Trial Profile

Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REP 2055 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Proof of concept
Sponsors REPLICor

Most Recent Events

07 Jun 2016 Results published in the journal PLOS ONE, according to a REPLICor media release.
07 Jun 2016 Results published in a REPLICor media release.
06 Nov 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com